Wockhardt Limited created its US subsidiary Wockhardt USA in early 2004 with a modest portfolio of three FDA–approved generic products.  Since inception, Wockhardt’s business has increased in the US. Today, Wockhardt USA LLC is leading the way in developing the most complete, high-quality line of generic oral solids, liquids, topicals, and injectables available in the United States. Wockhardt USA now represents more than 20% of Wockhardt Ltd’s global business, providing more than 220 NDCs spanning more than 75 different product families. We have been producing and distributing quality products in the United States for more than 14 years and have received over 110 ANDA approvals to date.

Chicago-based Morton Grove Pharmaceuticals was acquired by Wockhardt Limited in October 2007 in order to expand Wockhardt’s product line in the US. Since 1995, Morton Grove has been a leading manufacturer and marketer of oral liquid and topical pharmaceuticals. The company’s core products are manufactured in its 125,000 square foot, state-of-the-art facility.

Manufacturing

Pharmaceutical

Wockhardt USA

Kurt Orlofski

Somaly Keo

Jaroslaw Chetkowski

Diana Kiskinova

Ms-Ra Shreyas Parab

Darshan Lalwani

Kelly Li

Jamie Maguire

Bradley Ripka

Patrick Taaffe

Lily Llorens

The Leadership Team at Wockhardt USA is responsible for overseeing the strategic direction and overall management of the company. This includes driving business growth, ensuring operational efficiency, and maintaining the highest quality standards across all product lines. They lead efforts in regulatory compliance, supply chain optimization, and data-driven decision-making to sustain the company's market position and expand its product offerings in the US.

Leadership Team

Chemistry and Analytical Team

Leadership Team

About

Team members

Other teams at Wockhardt USA

Chemistry and Analytical Team